Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Galectin Therapeutics ( (GALT) ) just unveiled an update.
At the 2025 Annual Meeting of Stockholders on December 3, 2025, Galectin Therapeutics‘ stockholders elected the nominated directors and approved a non-binding advisory resolution on executive compensation. They also ratified Cherry Bekaert LLP as the independent registered public accounting firm for the year ending December 31, 2025. The board decided to conduct advisory votes on executive compensation every three years.
The most recent analyst rating on (GALT) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Galectin Therapeutics stock, see the GALT Stock Forecast page.
Spark’s Take on GALT Stock
According to Spark, TipRanks’ AI Analyst, GALT is a Underperform.
Galectin Therapeutics is a high-risk investment due to its challenging financial position, characterized by no revenues and high financial losses. However, the company’s progress in clinical trials and potential partnerships offer a positive long-term outlook. Technical indicators suggest mixed short-term momentum, while traditional valuation metrics are less applicable due to ongoing losses and the absence of dividends.
To see Spark’s full report on GALT stock, click here.
More about Galectin Therapeutics
Average Trading Volume: 373,572
Technical Sentiment Signal: Buy
Current Market Cap: $370.1M
See more data about GALT stock on TipRanks’ Stock Analysis page.